Regeneron Pharmaceuticals Inc (REGN) Director Joseph L. Goldstein Sells 1,000 Shares
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) opened at $330.69 on Thursday. Regeneron Pharmaceuticals Inc has a 52 week low of $313.53 and a 52 week high of $543.55. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $34,871.48, a price-to-earnings ratio of 23.49, a P/E/G ratio of 1.34 and a beta of 1.47.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the prior year, the company earned $3.04 EPS. The firm’s revenue was up 28.9% compared to the same quarter last year. equities analysts predict that Regeneron Pharmaceuticals Inc will post 14.13 earnings per share for the current year.
Several equities research analysts have commented on the company. BTIG Research restated a “buy” rating and issued a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price objective on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, November 27th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $480.00 to $380.00 in a research note on Friday, December 1st. Cowen reaffirmed a “hold” rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 7th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, November 13th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $463.19.
TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals Inc (REGN) Director Joseph L. Goldstein Sells 1,000 Shares” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://theolympiareport.com/2018/02/15/regeneron-pharmaceuticals-inc-regn-director-joseph-l-goldstein-sells-1000-shares.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.